Trial · NCT03245151
Results by group51
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 51
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib in Combination With Everolimus | Phase 1: Lenvatinib + Everolimus (All Participants) | 11 | milligram per square meter (mg/m^2) | ||
| Phase 1: Recommended Phase 2 Dose (RP2D) of Lenvatinib in Combination With Everolimus | Phase 1: Lenvatinib + Everolimus (All Participants) | 11 | mg/m^2 | ||
| Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | 5 | Participants | ||
| Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 | 18 | Participants | ||
| Phase 1: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE) | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | 2 | Participants | ||
| Phase 1: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE) | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 | 12 | Participants | ||
| Phase 2: Objective Response Rate (ORR) at Week 16 | Phase 2: Cohort 1, Ewing Sarcoma | 0.0 | 95% Confidence Interval 0.0 | percentage of participants | |
| Phase 2: Objective Response Rate (ORR) at Week 16 | Phase 2: Cohort 2, Rhabdomyosarcoma | 10.0 | 95% Confidence Interval 1.2 | percentage of participants | |
| Phase 2: Objective Response Rate (ORR) at Week 16 | Phase 2: Cohort 3, HGG | 0 | 95% Confidence Interval 0.0 | percentage of participants | |
| Phase 1: Objective Response Rate (ORR) | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | 0.0 | 95% Confidence Interval 0.0 | percentage of participants | |
| Phase 1: Objective Response Rate (ORR) | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 | 0.0 | 95% Confidence Interval 0.0 | percentage of participants | |
| Phase 2: Objective Response Rate (ORR) | Phase 2: Cohort 1, Ewing Sarcoma | 0.0 | 95% Confidence Interval 0.0 | percentage of participants | |
| Phase 2: Objective Response Rate (ORR) | Phase 2: Cohort 2, Rhabdomyosarcoma | 10.0 | 95% Confidence Interval 1.2 | percentage of participants | |
| Phase 2: Objective Response Rate (ORR) | Phase 2: Cohort 3, HGG | 0.0 | 95% Confidence Interval 0.0 | percentage of participants | |
| Phase 1: Disease Control Rate (DCR) | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | 20.0 | 95% Confidence Interval 0.5 | percentage of participants | |
| Phase 1: Disease Control Rate (DCR) | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 | 50.0 | 95% Confidence Interval 26.0 | percentage of participants | |
| Phase 2: Disease Control Rate (DCR) | Phase 2: Cohort 1, Ewing Sarcoma | 40.0 | 95% Confidence Interval 12.2 | percentage of participants | |
| Phase 2: Disease Control Rate (DCR) | Phase 2: Cohort 2, Rhabdomyosarcoma | 40.0 | 95% Confidence Interval 19.1 | percentage of participants | |
| Phase 2: Disease Control Rate (DCR) | Phase 2: Cohort 3, HGG | 30.0 | 95% Confidence Interval 6.7 | percentage of participants | |
| Phase 1: Clinical Benefit Rate (CBR) | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | 20.0 | 95% Confidence Interval 0.5 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03245151/results